physician photo

S. Peter Goedegebuure, PhD

  • Research Associate Professor of Surgery

Graduate School

PhD, Erasmus University Rotterdam, The Netherlands, 1985-1989

Post Doctoral Education

Postdoctoral Fellow, Department of Microbiology, University of Southern California Cancer Center, Los Angeles, CA, 1989-1991

Postdoctoral Fellow, Division of Surgical Oncology, Department of Surgery, Brigham and Women’s Hospital, Boston, MA, 1991-1993

Research Interests

NIH, DOD, Susan G. Komen for the Cure
Immune response to breast and pancreas cancer
Mechanisms of immune system recognition of cancer
Identification of tumor antigens on breast and pancreas cancer
Development of vaccines for treatment

Selected Publications

Spitzer D, Simon PO Jr, Kashiwagi H, Xiu J, Zeng C, Vangverawong S, Zhou D, Chang G, McDunn JE, Hornick JR, Goedegebuure PS, Hotchkiss RS, Mach RH, Hawkins WG. Use of multifunctional sigma-2 receptor ligand conjugates to trigger cancer-selective cell death signaling. Cancer Res. 2012;72:201-209. PMID: 22065721.

Porembka MR, Mitchem JB, Belt BA, Hsieh C, Herndon J, Gillanders WE, Lin G, Linehan DC, Goedegebuure P. Pancreatic adenocarcinoma induces bone marrow mobilization of myeloid-derived suppressor cells which promote primary tumor growth. Cancer Immunol Immunother. 2012, Jan 4 Epub. PMID: 22215137.

Li L*, Goedegebuure P*, Mardis ER, Ellis MJC, Zhang X, Herndon JM, Fleming TP, Carreno BM, Hansen TH, Gillanders WE. Cancer genome sequencing and its implications for personalized cancer vaccines. Cancers 2011;3:4191-4211. *Equal contribution.

Dodson L, Hawkins WG, Goedegebuure P. Potential targets for pancreatic cancer immunotherapeutics. Immunotherapy 2011;4:517-537. PMID: 21463193.

Goedegebuure P, Mitchem JB, Porembka MR, Tan MCB, Belt BA, Wang-Gillam A, Gillanders WE, Hawkins WG, Linehan DC. Myeloid-derived suppressor cells: general characteristics and relevance to clinical management of pancreatic cancer. Curr Cancer Drug Targets 2011;11:734-751. PMID: 21599634.

Hornick JR, Xu J, Vangverawong S, Tu Z, Mitchem JB, Spitzer D, Goedegebuure P, Mach RH, Hawkins WG. The novel sigma-2 receptor ligand SW43 stabilizes pancreas cancer progression in combination with gemcitabine. Mol Cancer 2010;9:298. PMID: 21092190.

Gnerlich JL, Mitchem JB, Weir JS, Sankpal NV, Kashiwagi H, Belt BA, Herndon JM, Eberlein TJ, Goedegebuure PS, Linehan DC. Induction of Th17 cells in the tumor microenvironment improves survival in a murine model of pancreatic cancer. J Immunol 2010;185:4063-4071. PMID: 20805420.

Spitzer D, McDunn JE, Plambeck-Suess S, Goedegebuure PS, Hotchkiss RS, Hawkins WG. A genetically encoded multifunctional TRAIL trimer facilitates cell-specific targeting and tumor cell killing. Mol Cancer Ther. 2010, 9:2142-2151. PMID: PMID: 20571073.

Li L, Herndon JM, Truscott SM, Hansen TH, Fleming TP, Goedegebuure P, Gillanders WE. Engineering superior DNA vaccines: MHC class I single chain trimers bypass antigen processing and enhance the immune response to low affinity antigens. Vaccine 2010;28:1911-1918. PMID: 20188246.

Simon PO, McDunn JE, Kashiwagi H, Chang K, Goedegebuure PS, Hotchkiss RS, Hawkins WG. Targeting AKT with the pro-apoptotic peptide, TAT-CTMP: a novel strategy for the treatment of human pancreatic adenocarcinoma. Int J Cancer 2009;125:942-951. PMID: 19405118.

Pub Med for S. Peter Goedegebuure, Ph.D.